SEC Tracker
Get the app

Plus Therapeutics CNSY

Plus Therapeutics FY 2021: net loss $13.4M; diluted EPS −$462.50

Form
10-K
Filed
Period
Importance
Notable
Document
10-K
Exhibit 10.2
Material contract
Exhibit 10.26
Material contract

Key figures from this report

These are the numbers Plus Therapeutics reported for the year ended Dec 31, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$13.4MAgainst −$8.2M in FY 202010-K income statement, on EDGAR
  2. Diluted EPS−$462.50No year-earlier figure tagged. Split-adjusted, as the tables show it; the filing reported −$1.1110-K income statement, on EDGAR
  3. Cash and cash equivalents$18.4M+120% from $8.3M in FY 202010-K balance sheet, on EDGAR
  4. Cash from operations−$10.3MAgainst −$8.4M in FY 202010-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Plus Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (3841) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Femasys FEMY public float $30M, Jun 30, 2025
  2. DarioHealth DRIO public float $28M, Jun 30, 2025
  3. HeartBeam BEAT public float $36M, Jun 30, 2025
  4. Nephros NEPH public float $27M, Jun 30, 2025
  5. RenovoRx RNXT public float $27M, Jun 30, 2025